Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 21, 2018
Pharmacy Choice - News - Pharmaceutical Development - May 21, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/21/18 - "Radiolabeled Active Targeting Pharmaceutical Composition and the Use Thereof" in Patent Application Approval Process (USPTO 20180117188)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors WANG, Hsin-Ell; HSIA, Chien-Chung; WENG, Mao-Chi; LIN, Kun-Liang; KAO, Hao-Wen; CHEN, Chao-Cheng; CHI, Kwan-Hwa; TIEN, Der-Chi; LIN, Wuu-Jyh, filed on September 14, 2017, was made available online on May 10, 2018, according to news reporting origina
5/21/18 - Akershus University Hospital Reports Findings in Multiple Sclerosis [Adherence to subcutaneous interferon beta-1a treatment using an electronic...
By a News Reporter-Staff News Editor at Clinical Trials Week Researchers detail new data in Autoimmune Diseases and Conditions- Multiple Sclerosis. According to news reporting out of Loerenskog, Norway, by NewsRx editors, research stated, "Disease modifying drugs help control the course of relapsing remitting multiple sclerosis; however, good adh
5/21/18 - Amneal Initiates Phase 3 Study for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa CD-LD in Advanced Parkinson's...
By a News Reporter-Staff News Editor at Pharma Business Week Amneal, a specialty pharmaceutical company, announced it has initiated a Phase 3 trial for IPX203. The IPX203 Phase 3 protocol has been agreed upon with the Food and Drug Administration in a Special Protocol Assessment. Keywords for this news article include: Antiparkinson Agents, Amnea
5/21/18 - AstraZeneca PLC Announces Lokelma approved in the US for the treatment of adults with hyperkalaemia
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "We are pleased by today's FDA approval of Lokelma as it enables us to help address a long-standing clinical need with a new medicine that offers rapid and sustained treatment for adults with hyperkalaemia. Steven Fishbane, MD, Profess
5/21/18 - AstraZeneca: FDA Approves Lokelma To Treat Adults With Hyperkalaemia
LONDON- British drug major AstraZeneca announced Monday that the US Food and Drug Administration or FDA has approved Lokelma, formerly ZS-9, for the treatment of adults with hyperkalaemia. The European Commission granted marketing authorisation for Lokelma in the European Union on March 22, 2018. Sean Bohen, Chief Medical Officer at AstraZeneca, sa
5/21/18 - BioClin Therapeutics, Inc., Completes $50 Million Series B Financing with Addition of New Investors
By a News Reporter-Staff News Editor at Clinical Trials Week BioClin Therapeutics, Inc., a clinical stage drug development company developing a first-in-class anti-FGFR3 monoclonal antibody for metastatic bladder cancer, announced expansion of its Series B financing to $50 million to broaden its clinical development activities.
5/21/18 - Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis...
By a News Reporter-Staff News Editor at Pharma Business Week Biohaven Pharmaceutical Holding Company Ltd. announced that it has established an expanded access program with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis. Biohaven anticipates submitting a New Drug Application for BHV-0223 to.
5/21/18 - Biolex Sells LEX System to Synthon and Initiates Sale of Locteron
By a News Reporter-Staff News Editor at Clinical Trials Week Biolex Therapeutics, Inc. announced that it has sold its LEX System, a proprietary platform for the development and production of biologics, to Synthon, a Netherlands- based specialty pharmaceutical company. Also included in the sale were two preclinical product candidates uniquely enab
5/21/18 - Cantargia Receives Notice of Allowance From Uspto for the Antibody Can03
Cantargia AB today announces that the United States Patent and Trademark Office has issued a Notice of Allowance for the company's patent application 15/ 501,710 directed to the antibody CAN03, which is of relevance for Cantargia's CANxx project.. Cantargia develops antibody based pharmaceuticals against the interleukin 1 receptor accessory prote
5/21/18 - Cardiovascular safety concerns over smoking-cessation drug misleading
By a News Reporter-Staff News Editor at Clinical Trials Week A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting "risk of serious adverse cardiovascular events associated with varenicline." "We found no clinically or statistically.
5/21/18 - Carnegie Mellon and McGill researchers challenge post-marketing trial practices
By a News Reporter-Staff News Editor at Clinical Trials Week PITTSBURGH- Current research ethics focuses on protecting study participants, but according to bioethicists from Carnegie Mellon University and McGill University, these efforts fail to prevent problems that undermine the social value of research. Published in Science, CMU's Alex John Lo
5/21/18 - Celsion Announces ThermoDox Commercial Supply Agreement With Hisun
By a News Reporter-Staff News Editor at Pharma Business Week Celsion Corporation, a leading oncology drug development company, announced that it has signed a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd., a leading pharmaceutical company in China, for the production of ThermoDox , Celsion's proprietary...
5/21/18 - Christopher Scully Joins PPD as Chief Financial Officer
By a News Reporter-Staff News Editor at Pharma Business Week Pharmaceutical Product Development, LLC announced the appointment of Christopher Scully as executive vice president and chief financial officer. Scully most recently served at Pfizer, Inc. as chief commercial officer for the Pfizer essential health business unit. During his 21 years wit
5/21/18 - Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy...
Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online. By a News Reporter-Staff News Editor at Pharma Business Week Chugai Pharmaceutical Co., Ltd. announced that the long-term data from a global phase II study for nemoli
5/21/18 - Click Therapeutics Awarded National Institutes of Health NIH Grant for Clickotine Digital Therapeutic Study
By a News Reporter-Staff News Editor at Clinical Trials Week Click Therapeutics, Inc., has been awarded a National Institutes of Health Small Business Innovation and Research grant through the National Institute of Drug Abuse. Clickotine will be compared head to head with the National Cancer Institute's smoking cessation app QuitGuide.
5/21/18 - CStone Raises $260 million in Series B Financing to Advance Novel Cancer Therapies
By a News Reporter-Staff News Editor at Pharma Business Week CStone Pharmaceuticals announced the successful completion of a $260 million financing, the largest Series B funding in the history of the China biopharmaceutical industry. The investment was led by GIC Private Limited, Singapore's sovereign wealth fund, with participation from new inve
5/21/18 - Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with...
By a News Reporter-Staff News Editor at Clinical Trials Week Daiichi Sankyo Company, Limited announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its primary endpoint of significantly prolonging overall survival compared to salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD
5/21/18 - Data on Clinical Trials and Studies Detailed by Researchers at University of Ottawa (Prevalence, Risk Factors, and Clinical Consequences of Recurrent...
Data on Clinical Trials and Studies Detailed by Researchers at University of Ottawa. According to news reporting from Ottawa, Canada, by NewsRx journalists, research stated, "Rapid response teams are groups of health-care providers, implemented by hospitals to respond to distressed hospitalized patients on the hospital wards. The news correspondent
5/21/18 - Data on Science Reported by Researchers at Duke University (One and done: Reasons principal investigators conduct only one FDA-regulated drug trial)
Using the U.S. Food and Drug Administration's Bioresearch Monitoring Information System database, we conducted an online survey to identify factors that affect principal investigators' decisions to conduct only a single FDA- regulated drug trial. " These same top three barriers also affected investigators' decisions to no longer conduct FDA- regula
5/21/18 - Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China
The agreement also includes the license to Hisun of development and commercialization rights for Enzon's PEG-SN38, a novel, Phase II PEGylated version of SN38, in the territory of China. Once successfully PEGylated, Hisun will have the option to in-license the product candidates, based upon internal selection criteria, and will be fully responsible
5/21/18 - Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or...
By a News Reporter-Staff News Editor at Clinical Trials Week Exelixis, Inc. announced that IMblaze370, the phase 3 pivotal trial of atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, and cobimetinib, an Exelixis- discovered MEK inhibitor, did not meet its primary endpoint. Genentech, Exelixis'
5/21/18 - FDA Grants Priority Review to Genentech's Cancer Immunotherapy TECENTRIQ Atezolizumab for Initial Treatment of People With a Specific Type of...
FDA Grants Priority Review to Genentech's Cancer Immunotherapy TECENTRIQ Atezolizumab for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer. By a News Reporter-Staff News Editor at Cancer Vaccine Week Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company's...
5/21/18 - Findings from Takeda Pharmaceutical Company Broadens Understanding of Aspartic Acid Endopeptidases (A Randomized, Single-Center, Double-Blind,...
According to news reporting out of Osaka, Japan, by NewsRx editors, research stated, "Imarikiren hydrochloride is a novel direct renin inhibitor. Financial support for this research came from Takeda Pharmaceutical Company. Our news journalists obtained a quote from the research from Takeda Pharmaceutical Company, "Subjects were randomized within 1
5/21/18 - Findings from Takeda Pharmaceutical Company Broadens Understanding of Small Molecule Inhibitors (TP-064, a potent and selective small molecule...
According to news reporting from Fujisawa, Japan, by NewsRx journalists, research stated, "Protein arginine methyltransferase 4 is involved in a variety of biological processes and is considered as a candidate oncogene owing to its overexpression in several types of cancer. Our news journalists report that additional information may be obtained by.
5/21/18 - Flavonoid compound found in foods and supplements shown to prevent the formation of blood clots
By a News Reporter-Staff News Editor at Clinical Trials Week BOSTON- A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis. These new findings, led by investigators at Beth Israel Deaconess Medical
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415